From Seekingalpha · SA Transcripts · · 40s
Beam Therapeutics Reviews BEAM-301 Data for Glycogen Storage Disease
Beam Therapeutics shares initial Phase I/II results for BEAM-301 in Glycogen Storage Disease Type 1a.
In brief
Beam Therapeutics shares initial Phase I/II results for BEAM-301 in Glycogen Storage Disease Type 1a. Beam Therapeutics presented early clinical data showing BEAM-301's potential for Glycogen Storage Disease Type 1a patients. Originally reported by Seekingalpha.
Beam Therapeutics Presents BEAM-301 Data
Beam Therapeutics Inc. (BEAM) reviewed initial Phase I/II clinical data for BEAM-301 in Glycogen Storage Disease Type 1a patients.
“Beam Therapeutics Inc. ( BEAM ) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a”
Key Participants on Call
Holly Manning, VP of Investor Relations; John Evans, CEO; Amy Simon, CMO; and Giuseppe Ciaramella, President joined the conference call.
Data Presented at ESGCT Congress
The company shared findings from the ESGCT Annual Congress where BEAM-301 was tested on Glycogen Storage Disease Type 1a patients.
What to remember
Beam Therapeutics presented early clinical data showing BEAM-301's potential for Glycogen Storage Disease Type 1a patients.
